Caution

For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA PH-350 will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA PH-350 must be avoided.

The IMMUSORBA PH-350 is indicated for the treatment of plasma. Never run whole blood through the IMMUSORBA PH-350 and may cause blockage. Do not use the IMMUSORBA PH-350 with plasma containing a large amount of thrombocytes.

References

[Reviews of the product]
1) Kobayashi et al., Immunoadsorption using Immunosorb TR-35 and PH, Transfus Apher Sci, 56:661-5, 2017
2) Yamazaki et al., Immunoadsorption with PH-350, Thera Apher Dial, 7:85-90, 2003
3) Yoshiba et al., Hemofilter TR-35 and PH: basis of design and features of function, Thera Apher 4:121-134, 2003

[Reviews in clinical use]
1) Yamaguchi, Immunoadsorption for collagen and rheumatic diseases, Transfus Apher Sci, 56:660-70, 2017
2) Yoshiba et al., Use of adsorption in critical-care, Transfus Apher 4:151-168, 2002
3) Togawa et al., Ability to remove immunoglobulins and anti-glomerular antibodies by plasma exchange, double filtration plasmapheresis and immunoadsorption, J Nephrol, 15:95-105, 1996
4) Yamazaki, Extracorporeal immunoadsorption, Therapeutic Plasmapheresis 4:133-137, 1986

[Pre-clinical & Development]
1) Yamazaki et al., Extracorporeal immunoadsorption on IMPH or IMTR column, Biomedical Artif Cells Artif Organs, 17:117-124, 1989

[Application to SLE]
2) Luo et al., Immunoadsorption and plasma exchange are equally efficacious as adjuvant therapies for severe lupus nephritis. Transfus Apher Sci, 42:335-40, 2010
5) Gauthier et al., Immunoadsorption in systemic lupus erythematosus: different techniques and their role in medical therapy, Thera Apher Dial, 7:18-184, 2003
6) Gauthier et al., Perspective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus, J Autoimmun, 11:409-11, 1999
8) Sugimura et al., Significance of Immunoadsorption Therapy in Patients with Systemic Lupus Erythematosus: Analysis of Serum Autobody and Immune Complexes by a Bioelectronic Flowing Column, Therapeutic Plasmapheresis (13) 590-597, 1993
9) Arakawa et al., Effect of Immunoadsorption Therapy on Lupus Nephritis Using Immunoadsorption PH-350 Column, Therapeutic Plasmapheresis (13) 88-92, 1999
10) Yamazaki et al., Immunoadsorption (IM-P) plasma perfusion in patients with rheumatoid arthritis or SLE, Life Support Symp, 1:189-191, 1983

[Application to RA]
2) Kobayashi et al., Plasma Clearing Using Immunoadsorbent IM-P for Patients with Rheumatoid Arthritis, Therapeutic Plasmapheresis (N) 152-157, 1984
3) Olloway et al., Effect of immunoadsorbent treatment on auto-antibody levels. Therapeutic Plasmapheresis (N) 149-152, 1986

[Other application]
3) Aminzadeh et al., Plasmapheresis Therapy in Progressive Systemic Sclerosis, Therapeutic Plasmapheresis (N) 87-100, 1989
Selective immunoadsorption for autoimmune diseases with easy to handle single use column

Indication
Autoimmune diseases
(e.g., Systemic lupus erythematosus (SLE), Malignant rheumatoid arthritis (MRA), Guillain-Barré syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy (CIDP), Multiple sclerosis (MS))

Features of IMMUSORBA PH-350(L)
- Therapeutic plasmapheresis by removing pathogenic substances from patient’s plasma by selective adsorption.
- No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
- Applicable to patients with protein allergy.

Clinical Course
- Changes in creatinine clearance. (P<0.05 vs. baseline).

Circuit Diagram

Specifications

<table>
<thead>
<tr>
<th>Immunoadsorption Column</th>
<th>Adsorbent</th>
<th>Material</th>
<th>Phenylalanine immobilized polymethylmethacrylate gel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Volume</td>
<td>350mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Priming Volume</td>
<td>300mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Container</td>
<td>Material</td>
<td>Polypyrrole</td>
</tr>
<tr>
<td></td>
<td>Weight</td>
<td>650g</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sterilization</td>
<td>High pressure steam</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Microparticle Filter</th>
<th>Material</th>
<th>Area</th>
<th>0.07m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filter</td>
<td>Material</td>
<td>Poly(vinyl alcohol) copolymer</td>
<td></td>
</tr>
<tr>
<td>Container</td>
<td>Material</td>
<td>Poly (vinyl chloride)</td>
<td></td>
</tr>
<tr>
<td>Priming Volume</td>
<td>30m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sterilization</td>
<td>Ethylene oxide</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>